Status:
RECRUITING
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-s...
Eligibility Criteria
Inclusion
- Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
- Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
- Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Exclusion
- History of or with active interstitial lung disease or pulmonary fibrosis.
- Active, known, or suspected autoimmune disease.
- Serious uncontrolled medical disorders.
- New onset, non-catheter-associated venous thromboembolism within the past 6 months.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Key Trial Info
Start Date :
October 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 14 2027
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT06544655
Start Date
October 10 2024
End Date
October 14 2027
Last Update
October 21 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona Cancer Center
Tucson, Arizona, United States, 85719
2
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
3
START Midwest
Grand Rapids, Michigan, United States, 49546
4
Sanford Cancer Center
Sioux Falls, South Dakota, United States, 57104